Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial

Trial Profile

An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Hydroxycarbamide
  • Indications Head and neck cancer; Human papillomavirus infections; Oropharyngeal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms OPTIMA
  • Most Recent Events

    • 27 Nov 2018 Results published in the Annals of Oncology
    • 31 Aug 2018 Biomarkers information updated
    • 07 Mar 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top